Takeda’s Entyvio Defends Share Against Janssen’s Stelara in the Crohn’s Disease Market, and Pressure in the Ulcerative Colitis Market May Heat Up in Early 2018 if Pfizer’s Xeljanz Secures an FDA Win
According to a new report by Spherix Global Insights, Janssen’s Remicade is taking a dual hit from the expansion of alternative mechanism of action biologics such as Entyvio and Stelara as well as the slow, but growing, adoption of infliximab biosimilars in the IBD market Download Report Overview EXTON, Pa. Nov. 21, 2017 /PRNewswire/ — […]
RealTime Dynamix™: Crohn’s Disease US Q2
Crohn’s Disease (CD) is a common form of inflammatory bowel diseases, currently affecting the lives of approximately 700,000 Americans. Theintroduction of biologics has changed the face of treatment for moderateto-severe CD patients. However, recent launches, an active pipeline, and the imminent introduction of biosimilars present an opportunity for major future shifts in the CD landscape. […]
The Battle for Preferred Alternative Mechanism Biologic in Crohn’s Disease Heats Up as Launch of Janssen’s Stelara Approaches the Six-Month Mark
While gastroenterologists report a strong intent to increase future prescribing, they are quite divided about whether Stelara will displace Takeda’s Entyvio as the alternate mechanism share leader, according to the latest report by Spherix Global Insights Download Report Overview March 20, 2017 – Cambridge, Massachusetts. Spherix Global Insights has released “RealTime Dynamix: Crohn’s Disease, Q1 […]
